TRBV20-1
T cell receptor beta variable 20-1
Also known as: TCRBV20S1, TCRBV2S1, TRBV201, TVBT1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- A0A075B6N2
- Gene
- TRBV20-1
- Ensembl
- ENSG00000211747
- Chromosome
- 7
- Canonical length
- 111 aa
- Protein class
- Predicted intracellular proteins, T-cell receptor genes
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Predicted to be involved in cell surface receptor signaling pathway. Predicted to be part of T cell receptor complex. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2025]
Canonical amino-acid sequenceUniProt
111 residues, UniProt reviewed canonical sequence.
>A0A075B6N2|TRBV20-1
1 MLLLLLLLGP GSGLGAVVSQ HPSRVICKSG TSVKIECRSL DFQATTMFWY RQFPKQSLML
61 MATSNEGSKA TYEQGVEKDK FLINHASLTL STLTVTSAHP EDSSFYICSA RLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRBV20-1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Highest tissue expression
- 150 nTPM
Expression across tissuesHPA
Tissue
- thymus: 150 nTPM
- lymph node: 50 nTPM
- appendix: 13 nTPM
- spleen: 6.9 nTPM
- tonsil: 5.6 nTPM
- small intestine: 5.5 nTPM
Single-cell type
- t-cells: 0.2 nCPM
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
- alveolar cells type 1: 0 nCPM
- alveolar cells type 2: 0 nCPM
Immune cell
- T-reg: 355 nTPM
- MAIT T-cell: 234 nTPM
- memory CD4 T-cell: 195 nTPM
- naive CD4 T-cell: 145 nTPM
- memory CD8 T-cell: 77 nTPM
- naive CD8 T-cell: 60 nTPM
Brain region
- pons: 3.5 nTPM
- medulla oblongata: 1.5 nTPM
- midbrain: 0.8 nTPM
- white matter: 0.8 nTPM
- cerebellum: 0.7 nTPM
- cerebral cortex: 0.6 nTPM
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRBV20-1 as an antibody target. Whether an autoantibody or antibody against TRBV20-1 could matter depends on whether native TRBV20-1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRBV20-1 is annotated at the cell surface, where native TRBV20-1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TRBV20-1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...